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According with the EULAR recommendations three treatment modali-
ties can been proposed: non-pharmacological, pharmacological, and
surgical. In many patients these modalities should be combined,
tailored to individual needs and risk factors.
Although non-pharmacological therapies are important in the
management of HOA, high quality evidence is lacking. The exercise
seems useful when combined with education and joint protection.
Advice regarding the use of electrotherapy, thermotherapy, ultrasound,
TENS or laser therapy is conﬂicting, mainly due to the lack of eligible
studies. So, their inclusion in recommendations relies mainly on
consensus methods and expert opinion.
As regard as the pharmacological therapy, the most realistic aim is the
pain relief, due to limited evidence of reliable efﬁcacy in modifying
disease activity by drugs.
Among analgesics, paracetamol is considered as the ﬁrst choice and, if
successful, the preferred for long term, although evidence supporting
its use in HOA are few. In mild to moderate pain and when not many
joints are affected, topical treatments are a good option for many
aspects, including the cost effectiveness. If paracetamol or topical
NSAIDs are insufﬁcient, then the addition of opioid analgesics should be
considered, although the evidence supporting its use in HOA is poor.
In patients who respond inadequately to paracetamol or topical treat-
ments, oral NSAIDs or COX-2 inhibitor should be used in substitution or
in addition, possibly at lowest effective dose for the shortest period of
time and taking into account individual patient risk factors, including
age and comedications.
Intra-articular (IA) long-acting corticosteroid is effective for painful
ﬂares of OA, especially trapeziometacarpal joint (TMC) OA and so, it
should be considered as an adjunct to core treatment for the relief of
moderate to severe pain in people with HOA. There are contrasting
opinions on the usefulness of IA hyaluronan (HA) in all existing
recommendations. However, in two recent trials it seems more
favourable than IA steroids.
The most studied SYSADOA in HOA has been the chondroitin sulphate
(CS). In the recent 6 months RCT performed by Gabay, decrease in global
hand pain and improvement of hand function were signiﬁcantly more
pronounced in the CS than in the placebo group. This drug was also
evaluated as DMOAD, in two independent trials comparing CS with
placebo and chondroitin polysulphate (CPS) with placebo in erosive
HOA (EHOA). The results showed that over a 3-year period CS was no
more beneﬁcial than placebo, whereas CPS was more effective than
placebo in preventing radiographic progression.
The EHOA is the HOA subset deserving main attention by new treat-
ment strategies, due to its severity and poor outcome. So, anti-cytokines
biologic agents have been tested in some pilot studies using s.c. ana-
kinra, humira and IA inﬂiximab, with good results, as also conﬁrmed by
the ﬁrst RCT recently performed by Verbruggen, with Humira.
Surgery is uncommonly performed in HOA, and evidence for its effec-
tiveness is lacking. However, for HOA at the base of the thumb, evidence
does support effectiveness of surgical therapy when conventional
therapies have failed. These surgical interventions include tra-
peziectomy, arthrodesis, osteotomy, ligament reconstruction, and joint
replacement. Surgery for areas other than the thumb base is not yet
widely available as a treatment option.
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PATHOPHYSIOLOGY OF POST-TRAUMATIC ARTHRITIS
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Epidemiologic studies have ﬁrmly established the association between
acute joint injury and the increased risk for the subsequent develop-
ment and progression of osteoarthritis (OA). All of the joint tissues are
susceptible to traumatic injury, including the ligaments, menisci,
articular cartilage and periarticular bone, and to some extent the
natural history of the OA process is related to the magnitude, site and
extent of the initial joint injury. However, independent of the speciﬁc
site or target tissue affected by the injury, all of the joint tissues are
eventually affected by the osteoarthritic process. Multiple mechanisms
contribute to the pathogenesis of the osteoarthritic changes after a joint
injury and although much of the attention has focused on the adverse
effects of increased joint instability and altered joint mechanics, there is
evidence that the pathogenic process in many individual is in fact
attributable to the initial acute-impact injury to the articular surfaceand in some instances the adjacent subchondral bone. These impact
injuries not onlymay disrupt the structural integrity of these tissues but
also can induce acute as well as chronic adverse effects on the survival
and functional activities of the resident cell populations. With respect to
the articular cartilage these changes include de-regulation of the
synthetic and reparative capacity of the chondrocytes, as well as the
release of potent biological mediators such as reactive oxygen species,
proteolytic enzymes and proinﬂammatory cytokines. In addition,
although OA generally is not viewed as an inﬂammatory form of
arthritis there is evidence that synovial inﬂammation not only
contributes to joint symptoms but also plays a role in the structural and
functional deterioration of joint tissues in both post traumatic OA and
other forms of OA. De-regulated chondrocyte function and the release
of biologically active chondrocyte-derived factors or products from the
cartilage extracellular matrix have been implicated in the synovial
inﬂammation, and many of the synovial derived products in turn may
adversely affect the homeostasis of the adjacent articular cartilage and
bone. Studies have shown that the risk factors for OA initiation and
progression in patients with post traumatic OA are similar to those for
idiopathic OA in that systemic host factors and local biomechanical
factors interact and that obesity, female gender, and pre-existing early-
stage OA contribute signiﬁcantly to adverse radiographic and clinical
outcomes. There remains uncertainty regarding the long-term beneﬁt
of surgical interventions with respect to prevention or slowing the
development of OA, and there is a critical need for rigorous clinical and
laboratory studies to deﬁne the factors that are responsible for joint
deterioration in patients with traumatic joint injuries and for assessing
the impact of interventions on the status of joint tissues and function.
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PREVENTION OF OSTEOARTHRITIS
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Osteoarthritis (OA) is the most common joint disease and is estimated
to affect more than 8 million people in the UK alone. Underlying the
disease is a loss of the normal homeostasis of the joint with progressive
breakdown of tissues including articular cartilage and subchondral
bone leading to end-stage joint destruction and failure. For the patient,
quality of life is reduced because of the loss of movement and joint pain
increases to become continuous, even at rest. OA is deﬁned as a complex
disorder with three groups of risk factors: genetic, constitutional (e.g.,
ageing and obesity) and local (e.g., secondary to mechanical load and
joint injury).
Current treatment options are limited to analgesia and physiotherapy,
and to prosthetic joint replacement for end-stage disease. Management
of OA is aimed at alleviating symptoms but current treatments do not
address the disease process itself. There is an unmet need to develop
new treatment options that could halt disease progression, at an early
stage. In this respect, regenerative medicine (including tissue engi-
neering) offers the potential for a long-term solution via biological
regeneration, repair or replacement of the degenerate joint tissues.
Pioneering approaches to biological joint resurfacing include autolo-
gous chondrocyte implantation and marrow stimulation techniques
such as microfracture. The lecture will outline possible cell-based
therapy interventions to treatment or prevention of OA, with a partic-
ular focus onto secondary post-traumatic OA. Exogenous (autologous or
allogeneic) stem cells could be injected intra-articularly into affected
joints or implanted locally into a damaged tissue, for instance into
a defect of the articular cartilage, either in suspension or in combination
with a biomaterial. Stem cells could be transplanted either after culture-
expansion or as minimally manipulated, e.g. immediately after their
puriﬁcation from their tissue sources. However, important ongoing
issues relate to identity characterization and potency assessment of the
different types of stem cells and how they can be bioprocessed with
consistency and implanted for effective repair of the damaged joint
surface and degenerate joint tissues. Using stem cells in combination
with biomaterials, there is also the potential to create ex vivo biological
joint tissues such as menisci, or even a fully biological prosthesis.
Opportunities and challenges from a research perspective will be
discussed.
The arthritic joint also demonstrates apparent repair mechanisms that
can result in aberrant formation of cartilage and bone in the form of
chondro-osteophytes. This presumes existence of endogenous stem
cells in the joint. In this regard, we recently provided data on the
